HC Wainwright Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $40.00

Day One Biopharmaceuticals (NASDAQ:DAWN - Free Report) had its target price lowered by HC Wainwright from $50.00 to $40.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

DAWN has been the topic of several other research reports. Wedbush restated an outperform rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an overweight rating in a research note on Monday, April 22nd. Oppenheimer reissued a market perform rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Needham & Company LLC boosted their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a buy rating in a research report on Wednesday, April 24th. Finally, The Goldman Sachs Group reduced their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of Moderate Buy and an average price target of $37.67.

Day One Biopharmaceuticals Stock Performance

DAWN stock traded up $0.48 during trading on Tuesday, hitting $17.08. 1,776,926 shares of the company's stock traded hands, compared to its average volume of 891,229. The business has a fifty day simple moving average of $15.47 and a 200 day simple moving average of $14.12. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.04 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). Research analysts forecast that Day One Biopharmaceuticals will post -2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the completion of the sale, the chief executive officer now directly owns 721,813 shares in the company, valued at $11,007,648.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Charles N. York II sold 2,666 shares of the firm's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares of the company's stock, valued at $4,235,748.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jeremy Bender sold 7,615 shares of the business's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the completion of the transaction, the chief executive officer now owns 721,813 shares of the company's stock, valued at $11,007,648.25. The disclosure for this sale can be found here. Insiders have sold a total of 195,247 shares of company stock valued at $3,376,817 over the last quarter. 8.40% of the stock is owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its position in shares of Day One Biopharmaceuticals by 67.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company's stock valued at $278,000 after purchasing an additional 6,750 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company's stock worth $979,000 after buying an additional 1,445 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Day One Biopharmaceuticals by 89.0% during the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company's stock worth $999,000 after buying an additional 32,238 shares during the period. Wellington Management Group LLP grew its holdings in shares of Day One Biopharmaceuticals by 77.7% during the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company's stock valued at $3,051,000 after buying an additional 91,393 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company's stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. Hedge funds and other institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.